The FDA has approved a new drug called Rinvoq Lq (upadacitinib) for children ages 2 and older with active polyarticular juvenile idiopathic arthritis (pJIA). This is a type of arthritis that affects multiple joints and can cause pain, swelling, and stiffness. The drug is for patients who have not had enough relief from or could not tolerate one or more TNF blockers, which are another class of arthritis medicines.
Rinvoq Lq is a pill taken by mouth. It belongs to a class of drugs called JAK inhibitors. These drugs work by blocking certain signals in the body that cause inflammation. Inflammation is the body's response that leads to joint pain and swelling in arthritis. By reducing inflammation, Rinvoq Lq can help control the disease.
This approval gives doctors and families a new oral option for treating pJIA. It is not a cure, but it may help manage symptoms and improve quality of life. The approval is based on clinical studies that showed the drug worked in this age group. However, the drug is not recommended for use with other JAK inhibitors, biologic DMARDs, or strong immunosuppressants like azathioprine and cyclosporine.
If you are considering this treatment for your child, talk to your doctor. They can help decide if Rinvoq Lq is a good option based on your child's specific health needs and medical history. As with any medicine, there are potential risks and benefits that your doctor can explain.
